Skip Navigation LinksHome > October 2014 - Volume 18 - Issue 4 > Posttreatment Assessment of Women at Risk of Developing High...
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0000000000000012
Review Article

Posttreatment Assessment of Women at Risk of Developing High-Grade Cervical Disease: Proposal for New Guidelines Based on Data From The Netherlands

H. Uijterwaal, Margot MD1; Kocken, Mariëlle MD, PhD1; Berkhof, Johannes PhD2; Bekkers, Ruud L.M. MD, PhD3; H.M. Verheijen, Réne MD, PhD4; Helmerhorst, Theo J.M. MD, PhD5; Meijer, Chris J.L.M. MD, PhD,1

Collapse Box


Objective: Women treated for high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or grade 3 [CIN2/3]) face a significant risk of developing post-treatment disease. Therefore, in most European countries, they are monitored by cytologic testing at 6, 12, and 24 months after treatment. Although testing for high-risk types of the human papillomavirus (hrHPV) in the follow-up seems to be a valuable supplementary method, its use is not yet fully explored.

Methods: Besides reviewing the literature, we completed a long-term follow-up study describing the cumulative risk for CIN2/3 or cancer (CIN2+) of different hrHPV and cytology test results after treatment.

Conclusions: High-risk HPV testing improves the sensitivity to detect posttreatment CIN2/3 (relative sensitivity = 1.15, 95% confidence interval [CI] = 1.06–1.25), but the highest sensitivity (95%, 95% CI = 91%–98%) is reached by performing cotesting (both cytology and hrHPV). The CIN2+ risk after a single negative cotesting result taken 6 months after treatments was similar to the risk after 3 consecutive negative cytologic test results (5-y CIN2+ risk being 3.0% [95% CI = 1.5%–6.1%] and 2.9% [95% CI = 1.2%–7.1%], respectively). Women who test negative for cotesting at both 6 and 24 months after treatment have a minimal risk of developing CIN3+ in the next 5 years (0.0%, 95% CI = 0.0%–3.0%).

Recommendations: We propose a new posttreatment surveillance protocol, consisting of combined testing with both cytology and hrHPV at 6 and 24 months after treatment. After 2 negative cotesting results, women should be retested after 5 years.

Copyright © 2014 by the American Society for Colposcopy and Cervical Pathology


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.